Académique Documents
Professionnel Documents
Culture Documents
Nail tumors
Bertrand Richert, MD, PhD , Pauline Lecerf, MD, Marie Caucanas, MD,
Josette Andr, MD
Department of Dermatology, University Hospitals Brugmann, St Pierre and Queen Fabiolas Children Hospital,
Universit Libre de Bruxelles, CHU Saint Pierre, Rue Haute 322, 1000 Brussels, Belgium
Abstract Most neoplasms of the nail apparatus have different clinical appearances, courses, and biological
behaviors as compared with similar tumors located elsewhere on the skin. Some of these tumors are unique
to the nail, such as onychomatricoma. As a general rule, benign lesions respect the general architecture of the
nail apparatus, whereas malignant ones are destructive. Our review covers the most common nail tumors,
from benign ones to the most frequent nail malignancy, the squamous cell carcinoma, which actually is the
greatest simulator. We will also discuss new approaches to the diagnosis and treatment of melanoma of the
nail apparatus. Physicians should be aware of these conditions and their management.
2013 Elsevier Inc. All rights reserved.
Benign tumors
Pyogenic granuloma
Nail pyogenic granuloma (PG) is a relatively common
acquired benign vascular tumor that frequently involves the
nail apparatus, including the periungual tissues and the nail
bed. Nail PG is due to different causes that act through
various pathogenetic mechanisms. Histopathology shows
similar features in every type of PG, irrespective of the
original cause and location. When there is a single PG,
especially if it involves the nail bed, histological examination
is necessary to rule out malignant melanoma.
Most cases of nail PG involve one of the following types:
1. Drug-induced PG
A main characteristic of drug-induced PG is the involvement of multiple nails of both fingers and toes. Several
Corresponding author. Tel.: + 32 2 535 43 79; fax: + 32 2 477 31 11.
E-mail address: bertrand.richert@chu-brugmann.be (B. Richert).
0738-081X/$ see front matter 2013 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.clindermatol.2013.06.014
603
Glomus tumor
A glomus tumor is very common on the hand and
represents about 1% to 2% of all hand tumors.26 It arises
especially at the fingertips, because the glomus bodies of
Masson are numerous at that location. In up to 90% of the
cases, this condition affects women who are about 45 years
old.27 There are two main clinical presentations:
1. A small reddish or bluish spot of several millimeters (b 10
mm) in diameter that can be seen through the nail plate
(Figure 3, A).
2. A longitudinal erythronychia with distal notching or
overlying longitudinal fissure.
Pain is the leading symptom; it may be spontaneous or
provoked by the slightest trauma. Pinpoint pain occurs, and
this involves throbbing and exacerbation with pressure and
with variations in temperature, especially cold. Sometimes,
the pain is worse at night. One case reported that even
applying polish to the nail was unbearable.28
Several clinical tests are available for the clinical
diagnosis of glomus tumors. The first one is the Love pin
test, which involves probing with a blunt instrument (eg,
paperclip, pencil) to determine the most tender area. The
Hildreth test involves applying an inflatable cuff to the arm,
inflating it to more than 300 mm Hg of pressure, and then
repeating the Love pin test; the test is positive if the patient
does not experience any pain with probing. The cold
sensitivity test should result in increased pain with exposure
to cold (eg, an ice cube). One paper revealed that the cold
sensitivity test was 100% sensitive, specific, and accurate29;
the Hildreth test was found to be 71.4% sensitive, 100%
specific, and 78% accurate, and the Love pin test was found
to be 100% sensitive and 78% accurate. Additional help may
come from transillumination.30 Some researchers consider
clinical exploration to be typical enough to confirm the
diagnosis and exact location of a digital glomus tumor.31 The
differential diagnosis includes all causes of onychalgia, but it
604
B. Richert et al.
Glomus tumors show a high signal in T2-weighted images and
a strong enhancement after gadolinium injection; however, the
signal behavior may vary with the histologic nature (eg,
vascular, cellular, myxoid) of the lesion.36 The tumor limits are
usually sharp, with a peripheral pseudocapsule that results
from a reactional response of the surrounding connective
tissue. This capsule shows a very low signal on all sequences
and seems to be incomplete in about 25% of cases.37 Cortical
erosion that is only revealed by MRI is very common. MRI is
used to accurately determine the spatial location of the tumor
so that a precise and radical surgical resection can be
performed.38 It may also help with the detection of multiple
glomus tumors in the same fingertip.37 Recurrences were
previously thought to be the result of the incomplete removal
of the original tumor, but they may actually be attributed to
small, synchronous, satellite lesions.39 A series of 75 cases
involved a global recurrence rate of 17%, but no recurrence
was observed in the group of patients who underwent
preoperative MRI or ultrasound studies.40
The only treatment of this condition is the surgical
removal of the tumor, which results in the resolution of
symptoms. Some surgeons favor the direct approach after
nail plate avulsion through the nail bed (see Figure 3, B and
C) or the matrix with meticulous repair.41,42 An alternate
approach is the lateral incision. This incision allows for the
exposure of the dorsal distal phalanx without violating the
matrix, thereby reducing the risk of postoperative deformity.43 This lateral approach offers a more narrow view of the
tumor with a higher chance of incomplete excision as
compared with the transungual approach.27,44 It should be
recommended for lesions that are deep seated proximally.45
Subungual exostosis
605
Fig. 5
Fig. 4 Subungual exostosis. The tumor is lifting up the distal plate.
Note the collarette and the telangiectasias running on its surface.
Myxoid pseudocyst
Myxoid pseudocysts (MPCs) are quite common. Their
exact incidence and prevalence are not known, although it is
estimated that women are affected more than twice as often as
men.57 It is now believed that MPCs occur as a result of a
leakage of synovial fluid through a breach in the joint capsule
of the distal interphalangeal joint.58 This phenomenon is
promoted by the presence of osteophytes and the reduction of
the joint space from osteoarthritis.59 A study demonstrated
radiologic evidence of primary interphalangeal osteoarthritis
in 75% of MPC cases.60 Communication between the MPCs
Fig. 6
606
B. Richert et al.
Fig. 7
Fibrokeratoma
Acquired ungual fibrokeratoma (AFK) is a solitary,
benign, skin-colored, asymptomatic nodule with a hyperkeratotic tip and a narrow base that occurs mostly in the
periungual area. It has also been called garlic clove
fibroma.74 Trauma is thought to be a major causative factor.
Most AFKs emerge from the most proximal part of the
ventral aspect of the proximal nail fold. Their pressure on the
underlying thin matrix is responsible for the arising of a
longitudinal groove that runs the whole length of the plate
(Figure 8). Their sizes vary considerably from tiny to
prominent, and they may sometimes be bifid. Rarely, AFKs
originate from within the matrix and grow into the nail plate
to eventually emerge in the middle of the nail; these
intraungual fibrokeratomas are also called dissecting ungual
fibrokeratomas because they divide the nail plate (Figure 9).
Subungual fibrokeratomas that arise from the nail bed are
also rare (Figure 10). Histology is mandatory, because
Bowen's disease may present a pseudofibrokeratoma.75,76
The multiple lesions associated with tuberous sclerosis are
called Koenen tumors. They develop most commonly on the
toes around the time of puberty, and their number increases
with age (Figure 11). A thorough examination of the
integument confirms the diagnosis. No histologic difference
has been found between isolated AFKs and Koenen tumors.77
Treatment is surgical. After the complete exposition of the
base of the tumor according to its location (eg, reclining the
proximal nail fold for those that originate from its
undersurface, avulsion of the plate for the subungual ones),
its very base is severed. Superficial removal would result in
a recurrence.
Subungual keratoacanthoma
Subungual keratoacanthoma (SUKA) is a rare, benign,
rapidly growing, aggressive tumor that is usually situated
below the edge of the nail plate or in the most distal portion
of the nail bed. Its clinical presentation is stereotyped and
associated with a painful distal tip caused by an underlying
bony erosion when visualized with radiography. In a review
of 61 cases in 2001, the tumor occurred in men in 75% of
cases and was most predominant on the first three fingers,
particularly the thumb. The great toenail was affected in one
case only. Lesions were polydigital in 10 cases.78
SUKA is a rapidly growing tumor that can emerge within
weeks; it is always painful, and it is most often located on the
distal part of the nail bed. The lesion may start as a small and
painful keratotic nodule that is visible beneath the free edge
of the nail and that grows rapidly into a 1- to 2-cm lesion
within 4 to 8 weeks. Its typical gross appearance is a domeshaped nodule with a central plug of horny material filling
the crater (Figure 12). The lesion rapidly plunges deeper and
erodes the underlying bony phalanx. If the SUKA is located
more proximally under the nail fold, it may present as a
painful chronic paronychia.78,79 In women, the existence of
multiple SUKA may represent a late manifestation of
incontinentia pigmenti.
The pathogenesis of SUKA is still not understood. The
roles of trauma, 78 oncogenic human papillomavirus
(HPV),80 and, in one case, steel wool81 have been suggested
but never confirmed. There is a marked dyskeratosis in the
cutaneous lesions of the verrucous stage of IP as well as the
subungual tumors of IP, which suggests an increased
Fig. 10
607
Fig. 11
Fig. 12
608
as keratoacanthoma elsewhere, but they tend to be more
vertically oriented and to exhibit more dyskeratotic cells,
fewer neutrophils and eosinophils, and little or no fibrosis at
their base.88 Distinguishing keratoacanthoma from welldifferentiated SCC is sometimes difficult. Recent evidence
indicates that the nuclear factor kappa-B p50 subunit and
cortactin may be useful to distinguish between these two
conditions. Both the p50 subunit and cortactin had higher
levels of expression in keratoacanthoma than in SCC. Both
were localized to the basal cell layer of keratoacanthoma,
whereas they were scattered without polarity throughout the
SCC lesions.89 The expression of Ki-67 is much stronger in
SCC than in SUKA. In SUKA, if Ki-67 expression is
present, it is weak and localized to the basal cell layer.90
Previous recommendations for the treatment of SUKA
have been divergent, ranging from conservative local
excision to aggressive amputation. A review of 18 cases
treated with curettage showed that 86% of lesions did not
recur.85 The first-line treatment, therefore, is the removal of
the entire tumor with curettage of the cavity.91 Some authors
suggest Mohs micrographic surgery to limit any risk of
recurrence; however, this technique seems hardly feasible for
the curettage of a bony cavity.92 Most recurrences occur
within the first 5 months postoperatively, but long-term
follow up is mandatory, because recurrences have been
observed after as long as 22 months.78,91 Amputation should
be only considered for patients with multiple recurrences,
when massive bony destruction is present, or when SCC
cannot be ruled out.78,93 For painful subungual tumors of
incontinentia pigmenti, the first choice for treatment should
be acitretin.82
Onychomatricoma
Onychomatricoma is a rare benign tumor of the matrix that
was first described 20 years ago.94 Similar tumors of the nail
matrix have also been reported as onychoblastoma, unguioblastoma, and unguioblastic fibroma.95,96 This is a slowgrowing, painless tumor for which most patients seek medical
care only years after onset, mostly for cosmetic or functional
concerns. The vast majority of cases have been reported
among Caucasians and especially in Europe. The origins of
this condition remain obscure, and its presence among
individuals of African descent has been exceptionally
mentioned.97 Only one case has been clinically identified in
a child, but because no surgery was performed, there was no
confirmation of the diagnosis.98 The tumor affects mainly the
digit (75%), and it involves the middle finger in two thirds of
cases.99 Some cases have been reported on the lesser toes,100
and exceptional cases have involved several digits.101
Several clinical signs are striking enough to either make
the diagnosis or at least to arouse suspicion:
Longitudinal thickening of a part of the nail plate that
often spares a portion of the normal pinkish nail
B. Richert et al.
Transverse and longitudinal overcurvature of the affected
portion of the nail
Xanthonychia of the affected part of the affected nail
Longitudinal ridging that is sometimes quite prominent
on the surface of the nail
Splinter hemorrhages that are mostly proximal but
sometimes distal
Honeycomb cavities at the frontal margin of the thickened
nail plate
A nodule may be seen at the base of the longitudinal nail
dystrophy102 (Figure 13). Several unusual clinical variants
have been described, including a giant form103 an association
with dorsal pterygium,104,105 onychomycosis,106 or longitudinal melanonychia.106 Dermatoscopy helps with diagnosis
by demonstrating multiple perforations of the nail plate at its
free border. Recently, researchers reported that the analysis
of a nail clipping is a fast and minimally invasive method to
achieve the correct diagnosis of onychomatricoma by
differentiating onychomatricoma from subungual tumors
and excluding fungal infection with a periodic acid-Schiff
stain.107 Ultrasonic examination also seems promising. A
recent study demonstrated a hyperechoic tumoral lesion
affecting the matrix zone with hyperechoic linear spots and
projections into the interplate space.108 Magnetic resonance
imaging is typical; it reveals a tumor that is emerging from
the nail matrix with the same signal as normal epithelium and
with processes that extend into the thickened nail plate.109
Nail avulsion can be diagnostic as it exposes a villous tumor
emerging from the matrix that is evocative of a sea anemone;
the nail appears as a thickened funnel storing the filamentous
digitations of the matrix that fit into the holes of the proximal
nail extremity (Figure 14). Those digitations are onychogenic and responsible for the thickening of the nail plate.
Their length may occasionally be as such that clipping of the
free edge induces bleeding.110 Clinical features are characteristic, but onychomycosis and Bowen disease111 should be
ruled out.
The surgical removal of the tumor is the only option, and
the tumor should only be shaved. Because it is impossible to
replace the plate (which is altered and should undergo
609
Fig. 14 Avulsion reveals the villous tumor on the matrix and the
funnel-shaped plate.
Malignant tumors
Squamous cell carcinoma
SCC is the most frequent malignant tumor at the nail
apparatus. The in situ form, which is restricted to the
epidermis without disruption of the basal membrane, is
called Bowen disease. It is weakly aggressive, and slowly
evolves over several years. The prognosis for both in situ and
invasive forms of SCC is very good: metastases are
exceptional, 119,120 and only three deaths have been
reported.121-123 It may occur at any age during adulthood,
with a peak incidence between the ages of 50 and 69 years.
Men with SCC outnumber women with SCC at a ratio of 2:1.
Fingernails are selectively affected, especially the thumb, the
index finger, and the middle finger.124 The condition is
mainly monodactylic, but uncommon polydactylic forms
have also been reported.125-127
Of the multiple suggested causative factors (eg, ionizing
radiation, arsenic, pesticides, dyskeratosis congenita), it has
been demonstrated that oncogenic HPV plays a major role. It
is estimated that, through genitodigital transmission, HPV is
responsible for SCC of the nail apparatus (both the in situ and
invasive forms) in up to 60% of cases. Of these, serotype 16
has been isolated in 75% of cases.124 Other serotypes have
been more recently identified, including 2, 6, 11, 18, 26, 31,
34, 35, 56, 58, and 73.119,128-130 Almost one third of patients
with SCC of the nail apparatus have a history of HPVassociated genital disease (ie, genital warts, dysplasia, or
cancer of the cervix or anogenital region) or a sexual partner
with such a history. The average time between the onset of
the genital disease and the appearance of the nail tumor is
approximately 12 years. It seems that the risk of developing
610
B. Richert et al.
Fig. 16
Fig. 17
Verrucous carcinoma
Thirteen cases of verrucous carcinoma involving the nail
apparatus have been reported in the literature. This is a rare,
highly keratinizing variant of SCC that is characterized by
local aggressiveness but a low potential for metastasis. The
plantar form is also known as epithelioma cuniculatum.154
The clinical presentation is often misleading; this condition
often appears as a warty lesion that increases in size with time.
The nail beds of the thumb, the great toenail, and the fifth
toenail are the most common locations. A case involving the
fourth finger was recently reported.155 Long evolving lesions
with papillomatous digitations are quite typical. Mohs surgery
or en bloc excision followed by a full-thickness graft155 is the
treatment of choice, but, in advanced cases, amputation may
be mandatory. One case was successfully treated with the
intra-arterial infusion of methotrexate.156
Melanoma
Nail apparatus melanoma (NAM) is rare; according to
several series, it accounts for 0.18% to 2.8% of all cutaneous
melanomas.157 The estimated incidence reaches 0.1 per
100,000 people per year.158 The relative incidence of NAM
among African and Asian individuals is much higher than
that found among Caucasians: about 25% of melanomas are
located in the nail apparatus in Japanese and African
Americans, but the absolute incidence of NAM may well
be similar for all racial groups.157 The average age of onset is
during the sixth and seventh decades. NAM is unusual in
children, with only 13 reported cases to date.159 The thumb
and the great toenail are most frequently affected,160
probably as a result of the larger proportion of matrix on
these digits.161 NAM mainly arises from the nail matrix, but
it is also found in the nail bed and the lateral folds, which are
structures that contain melanocytes.162 Although trauma has
often been mentioned as a potential causative factor, no link
has been established with certainty.163 Ultraviolet radiation
is not responsible either: the nail plate acts as a barrier,164 the
matrix area where the melanoma arises is not directly
exposed to sunlight, and the similar frequency of NAM
among dark- and fair-skinned races suggests that pigmentation is not protective.157
In 76% of cases, NAM develops in the matrix; its first
symptom is a longitudinal melanonychia.165 The use of the
ABCDEF rule was suggested to help the clinician detect
611
Fig. 19 Hutchinson sign. The whole nail unit was removed and
demonstrated a melanoma in situ.
612
can therefore serve as a one-step surgical treatment for in situ
or minimally invasive melanoma, thereby dramatically
reducing the duration of postoperative disability.
Various excisional biopsy techniques have been described
to ensure histological diagnosis and to limit the risk of
postoperative dystrophy for a lesion that could turn out to be
benign.173 Incisional biopsy is not recommended, because it
does not allow for the complete histological examination of
the pigmented lesion.
In 30% of cases, NAM arises from the nail bed and
presents as a nodule that may be pigmented, an ulceration
with bleeding, an isolated fold pigmentation, an unexplained
monodactylic paronychia, or a partial destruction of the nail
plate.174 One should remember that about 20% to 30% of
cases of NAM are amelanotic.157 This condition is even
more treacherous when it manifests as a monodactylic
onychorrhexis.175
Unfortunately, the diagnosis of NAM is very often delayed,
and this is associated with a poor prognosis. This delay may be
attributed to patients who do not initially suspect the diagnosis
of cancer at that site and consult their physicians at a late stage
of disease, when swelling, ulceration, oozing or bleeding
occur. These clinical features are already associated with a
thick Breslow index.176 Only one third of patients with
longitudinal melanonychia seek medical advice157 (Figure 20).
The overall accuracy of dermatologists with regard to the
diagnosis of nail matrix melanoma presenting as a longitudinal
melanonychia remains low; it ranged from 46% to 55% in a
test of dermatologists with different levels of clinical
experience, and the level of expertise did not statistically
influence the correct diagnosis.177 The 5-year survival rate
was 88% for patients with a Breslow thickness of less than
2.5 mm and only 40% for patients with a thickness of more
than 2.5 mm.161
Until recently, traditional treatment was amputation at the
metacarpophalangeal joint. Some studies have demonstrated
that the level of amputation did not affect patient survival, as
long as the tumor was entirely excised.157,158,178 There are
no randomized or prospective studies that compare ampu-
B. Richert et al.
tation with local excision or that study different levels of
amputation. Available scientific data come from retrospective studies. These involved bias with regard to the choice of
the treatment: more distal amputation or local excision was
performed for less invasive lesions, whereas, for those
lesions with a thicker Breslow depth, amputation was
chosen. No study in the literature was able to demonstrate
a prognostic benefit in terms of survival or avoidance of local
recurrence and satellite or in-transit metastasis if a digit or toe
underwent complete amputation as compared with resection
in or distal to the proximal interphalangeal joint.179
Excision margins of nail apparatus melanoma remain
controversial. NAM poses a difficult challenge as a result of
the lack of surrounding tissue.180 It is difficult to add extradeep margins unless amputation or the removal of a layer of
bone occurs, because the matrix is fixed to the bone. There is
little available data to evaluate amputation through the distal
interphalangeal joint.158 Recent studies have evaluated local
excision. Moerhle et al. have compared the treatment of
NAM in 62 patients. All thicknesses were considered
together, which resulted in a mean thickness of 1.68 mm
(Breslow depth, 1 to 4 mm). Thirty-one cases were treated
with conservative functional surgery (ie, the removal of the
whole nail unit with resection of the processus unguicularis),
and 31 cases involved distal phalanx amputation. The
researchers did not find any significant differences in
recurrence or survival rate in the two groups that reached
92% in both areas at 5 years.179 More and more authors
report treating in situ and microinvasive NAM (Breslow
depth, b 0.5 mm) with the en bloc removal of the nail unit
with 5 to 10-mm margins, sometimes with a removal of a
layer of underlying bone,181 followed by a full-thickness
skin graft180,182-185 or the use of artificial dermis.186 These
reports have involved excellent survival rates as well as
optimal cosmetic and functional results. Several case series
have reported Mohs surgery, with encouraging results.187,188
Care should be taken to carefully remove the lateral horns of
the matrix, because they are the most common locations of
marginal recurrence188. However, this conservative approach still remains controversial.189,190
In routine clinical practice, two groups should be
distinguished: in situ melanomas and invasive melanomas.
For in situ melanomas, a complete resection of the nail unit
with histological control of the margins should be proposed
to the patient in accordance with the location of the tumor
and the patients occupation. This discussion should involve
the patient, his or her family, and the multidisciplinary
oncologic team. Special attention should be given to the
thumb, because it is the only opposable finger and it allows
for the grabbing and holding of objects. This is also true for
the big toe due to its main role as a support point and an
insertion site of important muscles for balance. Invasive
melanomas should undergo the most functional amputation
possible, depending on the tumor thickness.191 Adjuvant
systemic chemotherapy, isolated limb perfusion, and routine
elective lymph node dissection have been used, but no
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
References
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
613
614
41. di Chiacchio N, Richert B, Haneke E. Surgery of the matrix. In:
Richert B, di Chiacchio N, Haneke E, eds. Nail Surgery. London:
Informa; 2011; p. 103-132.
42. Lee D-W, Yang J-H, Chang S, et al. Clinical and pathological
characteristics of extradigital and digital glomus tumours: a retrospective comparative study. J Eur Acad Dermatol Venereol. 2011;25:
1392-1397.
43. Vasisht B, Watson HK, Joseph E, et al. Digital glomus tumors: a 29year experience with a lateral subperiosteal approach. Plast Reconstr
Surg. 2004;114:1486-1489.
44. Heim U, Hnggi W. Subungual glomus tumors. Value of the direct
dorsal approach. Ann Chir Main. 1985;4:51-54.
45. Hazani R, Houle JM, Kasdan ML, et al. Glomus tumors of the hand.
Eplasty. 2008;8:e48.
46. Lee SK, Jung MS, Lee YH, et al. Two distinctive subungual
pathologies: subungual exostosis and subungual osteochondroma.
Foot Ankle Int. 2007;28:595-601.
47. Murphey MD, Choi JJ, Kransdorf MJ, et al. Imaging of osteochondroma: variants and complications with radiologic-pathologic correlation. Radiographics. 2000;20:1407-1434.
48. Landon GC, Johnson KA, Dahlin DC. Subungual exostoses. J Bone
Joint Surg Am. 1979;61:256-259.
49. De Berker DA, Langtry J. Treatment of subungual exostoses by
elective day case surgery. Br J Dermatol. 1999;140:915-918.
50. Davis DA, Cohen PR. Subungual exostosis: case report and review of
the literature. Pediatr Dermatol. 1996;13:212-218.
51. Fleegler EJ, Zeinowicz RJ. Tumors of the perionychium. Hand Clin.
1990;6:113-133. [discussion 135136].
52. Schmitt AM, Bories A. Baran R (Subungueal exostosis of fingers in
hereditary multiple exostosis. 3 cases). Ann Dermatol Venereol.
1997;124:233-236.
53. Hoehn JG, Coletta C. Subungual exostosis of the fingers. J Hand Surg
Am. 1992;17:468-471.
54. Dumontier CA, Abimelec P. Nail unit enchondromas and osteochondromas: a surgical approach. Dermatol Surg. 2001;27:274-279.
55. Garca Carmona FJ, Pascual Huerta J, Fernndez Morato D. A
proposed subungual exostosis clinical classification and treatment
plan. J Am Podiatr Med Assoc. 2009;99:519-524.
56. Haneke E, Di Chiacchio N, Richert B. Surgery of the bony phalanx. In:
Richert B, di Chiacchio N, Haneke E, eds. Nail Surgery. London:
Informa; 2011. p. 149-164.
57. Sonnex TS. Digital myxoid cysts: a review. Cutis. 1986;37:89-94.
58. de Berker D, Lawrence C. Ganglion of the distal interphalangeal joint
(myxoid cyst): therapy by identification and repair of the leak of joint
fluid. Arch Dermatol. 2001;137:607-610.
59. Pietrzak A, Wojnowska D, Chodorowska G, et al. Multiple myxoid
cysts of both hands in a cashier: a case report. Ann Univ Mariae Curie
Sklodowska Med. 2003;58:478-481.
60. Lin Y-C, Wu Y-H, Scher RK. Nail changes and association of
osteoarthritis in digital myxoid cyst. Dermatol Surg. 2008;34:
364-369.
61. Drap JL, Idy-Peretti I, Goettmann S, et al. MR imaging of digital
mucoid cysts. Radiology. 1996;200:531-536.
62. De Berker DA, Lawrence CM. Treatment of myxoid cysts. Dermatol
Surg. 2001;27:296-299.
63. Connolly M, de Berker DAR. Multiple myxoid cysts secondary to
occupation. Clin Exp Dermatol. 2006;31:404-406.
64. de Berker D, Goettman S, Baran R. Subungual myxoid cysts: clinical
manifestations and response to therapy. J Am Acad Dermatol.
2002;46:394-398.
65. Mani-Sundaram D. Surgical correction of mucous cysts of the nail
unit. Dermatol Surg. 2001;27:267-268.
66. Epstein E. A simple technique for managing digital mucous cysts.
Arch Dermatol. 1979;115:1315-1316.
67. Bhler-Sommeregger K, Kutschera-Hienert G. Cryosurgical management of myxoid cysts. J Dermatol Surg Oncol. 1988;14:1405-1408.
B. Richert et al.
68. Dawber RP, Sonnex T, Leonard J, et al. Myxoid cysts of the finger:
treatment by liquid nitrogen spray cryosurgery. Clin Exp Dermatol.
1983;8:153-157.
69. Audebert C. Treatment of mucoid cysts of fingers and toes by injection
of sclerosant. Dermatol Clin. 1989;7:179-181.
70. Huerter CJ, Wheeland RG, Bailin PL, et al. Treatment of digital
myxoid cysts with carbon dioxide laser vaporization. J Dermatol Surg
Oncol. 1987;13:723-727.
71. Lonsdale-Eccles AA, Langtry JAA. Treatment of digital myxoid cysts
with infrared coagulation: a retrospective case series. Br J Dermatol.
2005;153:972-975.
72. Kasdan ML, Stallings SP, Leis VM, et al. Outcome of surgically
treated mucous cysts of the hand. J Hand Surg Am.. 1994;19:504-507.
73. Lawrence C. Skin excision and osteophyte removal is not required in
the surgical treatment of digital myxoid cysts. Arch Dermatol.
2005;141:1560-1564.
74. Stell HH. Garlic-clove fibroma. JAMA. 1965;29(191)1082-1083.
75. Baran R, Perrin C. Pseudo-fibrokeratoma of the nail apparatus with
melanocytic pigmentation: a clue for diagnosing Bowens disease.
Acta Derm Venereol. 1994;74:449-450.
76. Haneke E. Epidermoid carcinoma (Bowens disease) of the nail
apparatus simulating acquired ungual fibrokeratoma. Skin Cancer.
1991;6:217-221.
77. Kint A, Baran R. Histopathologic study of Koenen tumors. Are they
different from acquired digital fibrokeratoma? J Am Acad Dermatol.
1988;18(2 Pt 1):369372.
78. Baran R, Mikhail G, Costini B, et al. Distal digital keratoacanthoma: two
cases with a review of the literature. Dermatol Surg. 2001;27:575-579.
79. Lovett JE, Haines TA, Bentz ML, et al. Subungual keratoacanthoma
masquerading as a chronic paronychia. Ann Plast Surg. 1995;34:
84-87.
80. Baran R, Tosti A, De Berker D. Periungual keratoacanthoma preceded
by a wart and followed by a verrucous carcinoma at the same site. Acta
Derm Venereol. 2003;83:232-233.
81. Oliwiecki S, Peachey RD, Bradfield JW, et al. Subungual keratoacanthomaa report of four cases and review of the literature. Clin Exp
Dermatol. 1994;19:230-235.
82. Young A, Manolson P, Cohen B, et al. Painful subungal dyskeratotic
tumors in incontinentia pigmenti. J Am Acad Dermatol. 2005;52:
726-729.
83. Allen CA, Stephens M, Steel WM. Subungual keratoacanthoma.
Histopathology. 1994;25:181-183.
84. Levy DW, Bonakdarpour A, Putong PB, et al. Subungual keratoacanthoma. Skeletal Radiol. 1985;13:287-290.
85. Pellegrini Jr VD, Tompkins A. Management of subungual keratoacanthoma. J Hand Surg Am. 1986;11:718-724.
86. Sinha A, Marsh R, Langtry J. Spontaneous regression of subungual
keratoacanthoma with reossification of underlying distal lytic phalynx.
Clin Exp Dermatol. 2005;30:20-22.
87. Choi JH, Shin DH, Shin DS, et al. Subungual keratoacanthoma:
ultrasound and magnetic resonance imaging findings. Skeletal Radiol.
2007;36:769-772.
88. Stoll DM, Ackerman AB. Subungual keratoacanthoma. Am J
Dermatopathol. 1980;2:265-271.
89. Fujii M, Honma M, Takahashi H, et al. The nuclear factor kappa B p50
subunit and cortactin as markers to distinguish between keratoacanthoma and well-differentiated squamous cell carcinoma. Clin Exp
Dermatol. 2011;36:788-792.
90. Honma M, Kato N, Hashimoto M, et al. Subungual keratoacanthoma:
analysis of cell proliferation and copy number variation of oncogenes
compared with periungual squamous cell carcinoma. Clin Exp
Dermatol. 2011;36:57-62.
91. Patel MR, Desai S. Subungual keratoacanthoma in the hand. J Hand
Surg Am. 1989;14:139-142.
92. Andr J, Richert B. Subungual keratoacanthoma. Ann Dermatol
Venereol. 2012;139:68-72.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
615
of a distinctive soft tissue tumor with a predilection for the fingers and
toes. G Ital Dermatol Venereol. 2011;146:283-287.
McHugh RW, Hazen P, Eliezri YD, et al. Metastatic periungual
squamous cell carcinoma: detection of human papillomavirus type 35
RNA in the digital tumor and axillary lymph node metastases. J Am
Acad Dermatol. 1996;34:1080-1082.
Canovas F, Dereure O, Bonnel F. A propos of a case of epidermoid
carcinoma of the nail bed with intraneural metastasis to the median
nerve. Chir Main. 1998;17:232-235.
Dalle S, Depape L, Phan A, et al. Squamous cell carcinoma of the nail
apparatus: clinicopathological study of 35 cases. Br J Dermatol.
2007;156:871-874.
Kouskoukis CE, Scher RK, Kopf AW. Squamous-cel carcinoma of the
nail bed. J Dermatol Surg Oncol. 1982;8:853-855.
Alam M, Caldwell JB, Eliezri YD. Human papillomavirus-associated
digital squamous cell carcinoma: literature review and report of 21
new cases. J Am Acad Dermatol. 2003;48:385-393.
Riddel C, Rashid R, Thomas V. Ungual and periungual human
papillomavirus-associated squamous cell carcinoma: a review. J Am
Acad Dermatol. 2011;64:1147-1153.
Baran RL, Gormley DE. Polydactylous Bowens disease of the nail. J
Am Acad Dermatol. 1987;17(2 Pt 1):201-204.
Goodman G, Mason G, OBrien T. Polydactylous Bowens disease of
the nail bed. Australas J Dermatol. 1995;36:164-165.
Strong ML. Bowens disease in multiple nail bedscase report.
J Hand Surg Am. 1983;8:329-330.
Shimizu A, Tamura A, Abe M, et al. Detection of human
papillomavirus type 56 in Bowens disease involving the nail matrix.
Br J Dermatol. 2008;158:1273-1279.
Forslund O, Nordin P, Andersson K, et al. DNA analysis indicates
patient-specific human papillomavirus type 16 strains in Bowens
disease on fingers and in archival samples from genital dysplasia. Br J
Dermatol. 1997;136:678-682.
Kawashima M, Jablonska S, Favre M, et al. Characterization of a new
type of human papillomavirus found in a lesion of Bowens disease of
the skin. J Virol. 1986;57:688-692.
Hale LR, Dawber RP. Subungual squamous cell carcinoma presenting
with minimal nail changes: a factor in delayed diagnosis? Australas J
Dermatol. 1998;39:86-88.
Fleckman P, Bernstein G, Barker E. Squamous cell carcinoma of the
nail bed treated as chronic paronychia and wart for fourteen years.
Cutis. 1985;36:189-191.
Mikhail GR. Subungual epidermoid carcinoma. J Am Acad Dermatol.
1984;11(2 Pt 1):291-298.
Baran R, Perrin C. Longitudinal erythronychia with distal subungual
keratosis: onychopapilloma of the nail bed and Bowens disease. Br J
Dermatol. 2000;143:132-135.
Baran R, Simon C. Longitudinal melanonychia: a symptom of
Bowens disease. J Am Acad Dermatol. 1988;18:1359-1360.
Sass U, Andr J, Stene JJ, et al. Longitudinal melanonychia revealing
an intraepidermal carcinoma of the nail apparatus: detection of
integrated HPV-16 DNA. J Am Acad Dermatol. 1998;39:490-493.
Baran R, Eichmann A. Longitudinal melanonychia associated with
Bowens disease: two new cases. Dermatology (Basel). 1993;186:
159-160.
Saijo S, Kato T, Tagami H. Pigmented nail streak associated with
Bowens disease of the nail matrix. Dermatologica. 1990;181:156-158.
Inokuma D, Aoyagi S, Saito N, et al. Bowens disease of the nail
matrix presenting as melanonychia: detection of human papillomavirus type 56. Acta Derm Venereol. 2009;89:638-639.
Lambiase MC, Gardner TL, Altman CE, et al. Bowen disease of the
nail bed presenting as longitudinal melanonychia: detection of human
papillomavirus type 56 DNA. Cutis. 2003;72:305-309. [quiz 296].
Sau P, McMarlin SL, Sperling LC, et al. Bowens disease of the nail
bed and periungual area. A clinicopathologic analysis of seven cases.
Arch Dermatol. 1994;130:204-209.
616
142. Andr J, Sass U, Theunis A. Diseases of the nail. In: Calonj E, Brenn
T, Lazar A, eds. McKees Pathology of the Skin. London: Elsevier;
2012. p. 1068-1069.
143. Goldminz D, Bennett RG. Mohs micrographic surgery of the nail unit.
J Dermatol Surg Oncol. 1992;18:721-726.
144. Dika E, Piraccini B, Balestri R, et al. Mohs surgery for squamous cell
carcinoma of the nail: report of 15 cases. Our experience and a longterm follow up. Br J Dermatol. 2012;167:1365-2133.
145. Lumpkin 3rd LR, Rosen T, Tschen JA. Subungual squamous cell
carcinoma. J Am Acad Dermatol. 1984;11(4 Pt 2):735-738.
146. Peterson SR, Layton EG, Joseph AK. Squamous cell carcinoma of the
nail unit with evidence of bony involvement: a multidisciplinary
approach to resection and reconstruction. Dermatol Surg.
2004;30(2 Pt 1):218-221.
147. Zaiac MN, Weiss E. Mohs micrographic surgery of the nail unit and
squamous cell carcinoma. Dermatol Surg. 2001;27:246-251.
148. de Berker DA, Dahl MG, Malcolm AJ, et al. Micrographic surgery
for subungual squamous cell carcinoma. Br J Plast Surg. 1996;49:
414-419.
149. Laffitte E, Saurat J-H. Recurrent Bowens disease of the nail:
treatment by topical imiquimod (Aldara). Ann Dermatol Venereol.
2003;130(2 Pt 1):211-213.
150. Sturm HM. Bowens disease and 5-fluorouracil. J Am Acad Dermatol.
1979;1:513-522.
151. Tan B, Sinclair R, Foley P. Photodynamic therapy for subungual
Bowens disease. Australas J Dermatol. 2004;45:172-174.
152. Usmani N, Stables GI, Telfer NR, et al. Subungual Bowens disease
treated by topical aminolevulinic acid-photodynamic therapy. J Am
Acad Dermatol. 2005;53(5 Suppl 1):S273-S276.
153. Sheen Y-S, Sheen M-C, Sheu H-M, et al. Squamous cell carcinoma of
the big toe successfully treated by intra-arterial infusion with
methotrexate. Dermatol Surg. 2003;29:982-983.
154. Van Geertruyden JP, Olemans C, Laporte M, et al. Verrucous
carcinoma of the nail bed. Foot Ankle Int. 1998;19:327-328.
155. Matoso A, Jellinek N, Telang GH. Verrucous carcinoma of the nail
unit. Am J Dermatopathol. 2012;34:e106-e110.
156. Sheen M-C, Sheen Y-S, Sheu H-M, et al. Subungual verrucous
carcinoma of the thumb treated by intra-arterial infusion with
methotrexate. Dermatol Surg. 2005;31(7 Pt 1)787-789.
157. Thai KE, Young R, Sinclair RD. Nail apparatus melanoma. Australas
J Dermatol. 2001;42:71-81. [quiz 8283].
158. Martin DE, English JC, Goitz RJ. Subungual malignant melanoma.
J Hand Surg Am.. 2011;36:704-707.
159. Tosti A, Piraccini BM, Cagalli A, et al. In situ melanoma of the nail
unit in children: report of two cases in fair-skinned Caucasian children.
Pediatr Dermatol. 2012;29:79-83.
160. Tan K-B, Moncrieff M, Thompson JF, et al. Subungual melanoma: a
study of 124 cases highlighting features of early lesions, potential
pitfalls in diagnosis, and guidelines for histologic reporting. Am J Surg
Pathol. 2007;31:1902-1912.
161. Banfield CC, Dawber RP. Nail melanoma: a review of the literature
with recommendations to improve patient management. Br J
Dermatol. 1999;141:628-632.
162. Koga H, Saida T, Uhara H. Key point in dermoscopic differentiation
between early nail apparatus melanoma and benign longitudinal
melanonychia. J Dermatol. 2011;38:45-52.
163. Mhrle M, Hfner HM. Is subungual melanoma related to trauma?
Dermatology (Basel). 2002;204:259-261.
164. Stern DK, Creasey AA, Quijije J, et al. UV-A and UV-B penetration of
normal human cadaveric fingernail plate. Arch Dermatol. 201;147:
439-441.
165. Ishihara Y, Matsumoto K, Kawachi S, et al. Detection of early lesions
of ungual malignant melanoma. Int J Dermatol. 1993;32:44-47.
166. Levit EK, Kagen MH, Scher RK, et al. The ABC rule for clinical
detection of subungual melanoma. J Am Acad Dermatol. 2000;42(2 Pt
1):269-274.
B. Richert et al.
167. Andr J, Lateur N. Pigmented nail disorders. Dermatol Clin. 2006;24:
329-339.
168. Baran R, Kechijian P. Hutchinsons sign: a reappraisal. J Am Acad
Dermatol. 1996;34:87-90.
169. Tosti A, Argenziano G. Dermoscopy allows better management of nail
pigmentation. Arch Dermatol. 2002;138:1369-1370.
170. Ronger S, Touzet S, Ligeron C, et al. Dermoscopic examination of nail
pigmentation. Arch Dermatol. 2002;138:1327-1333.
171. Hirata SH, Yamada S, Enokihara MY, et al. Patterns of nail matrix and
bed of longitudinal melanonychia by intraoperative dermatoscopy. J
Am Acad Dermatol. 2011;65:297-303.
172. Debarbieux S, Hospod V, Depaepe L, et al. Perioperative confocal
microscopy of the nail matrix in the management of in situ or
minimally invasive subungual melanomas. Br J Dermatol. 2012;167:
828-836.
173. Jellinek N. Nail matrix biopsy of longitudinal melanonychia:
diagnostic algorithm including the matrix shave biopsy. J Am Acad
Dermatol. 2007;56:803-810.
174. Tosti A, Piraccini BM, de Farias DC. Dealing with melanonychia.
Semin Cutan Med Surg. 2009;28:49-54.
175. Andr J, Moulonguet I, Goettmann-Bonvallot S. In situ amelanotic
melanoma of the nail unit mimicking lichen planus: report of 3 cases.
Arch Dermatol. 2010;146:418-421.
176. Bristow IR, de Berker DA, Acland KM, et al. Clinical guidelines for
the recognition of melanoma of the foot and nail unit. J Foot Ankle
Res. 2010;3:25.
177. Di Chiacchio N, Hirata SH, Enokihara MY, et al. Dermatologists
accuracy in early diagnosis of melanoma of the nail matrix. Arch
Dermatol. 2010;146:382-387.
178. Finley 3rd RK, Driscoll DL, Blumenson LE, et al. Subungual
melanoma: an eighteen-year review. Surgery. 1994;116:96-100.
179. Moehrle M, Metzger S, Schippert W, et al. Functional surgery in
subungual melanoma. Dermatol Surg. 2003;29:366-374.
180. Duarte AF, Correia O, Barros AM, et al. Nail matrix melanoma in situ:
conservative surgical management. Dermatology (Basel). 2010;220:
173-175.
181. Chow WTH, Bhat W, Magdub S, et al. In situ subungual melanoma:
digit salvaging clearance. J Plast Reconstr Aesthet Surg. 2012;66:
274-276.
182. Lazar A, Abimelec P, Dumontier C. Full thickness skin graft for nail
unit reconstruction. J Hand Surg Br. 2005;30:194-198.
183. Rayatt SS, Dancey AL, Davison PM. Thumb subungual melanoma: is
amputation necessary? J Plast Reconstr Aesthet Surg. 2007;60:
635-638.
184. Sureda N, Phan A, Poulalhon N, et al. Conservative surgical
management of subungual (matrix derived) melanoma: report of
seven cases and literature review. Br J Dermatol. 2011;165:
852-858.
185. High WA, Quirey RA, Guilln DR, et al. Presentation, histopathologic
findings, and clinical outcomes in 7 cases of melanoma in situ of the
nail unit. Arch Dermatol. 2004;140:1102-1106.
186. Hayashi K, Uhara H, Koga H, et al. Surgical treatment of nail
apparatus melanoma in situ: the use of artificial dermis in
reconstruction. Dermatol Surg. 2012;38:692-694.
187. Banfield CC, Dawber RP, Walker NP, et al. Mohs micrographic
surgery for the treatment of in situ nail apparatus melanoma: a case
report. J Am Acad Dermatol. 1999;40:98-99.
188. Brodland DG. The treatment of nail apparatus melanoma with Mohs
micrographic surgery. Dermatol Surg. 2001;27:269-273.
189. Cohen T, Busam KJ, Patel A, et al. Subungual melanoma:
management considerations. Am J Surg. 2008;195:244-248.
190. Leiter U, Eigentler TK, Forschner A, et al. Excision guidelines and
follow-up strategies in cutaneous melanoma: facts and controversies.
Clin Dermatol. 2010;28:311-315.
191. Braun RP, Baran R, Le Gal FA, et al. Diagnosis and management of
nail pigmentations. J Am Acad Dermatol. 2007;56:835-847.
617
196. Engel E, Ulrich H, Vasold R, et al. Azo pigments and a basal cell
carcinoma at the thumb. Dermatology (Basel). 2008;216:76-80.
197. Brasie RA, Patel AR, Nouri K. Basal cell carcinoma of the nail unit
treated with Mohs micrographic surgery: superficial multicentric BCC
with jagged borders: a histopathological hallmark for nail unit BCC.
J Drugs Dermatol. 2006;5:660-663.
198. Bandyopadhyay D, Sen S. Periungual basal cell carcinoma: a
case report with review of literature. Indian J Dermatol. 2011;56:
220-222.